Immuno-Oncology NewsIn Phase 2 Trial, Orencia Prevented Graft-Versus-Host Disease After Stem Cell TransplantImmuno-Oncology NewsThe first group included 43 pediatric and adult patients who received four doses of Orencia, along with a calcineurin inhibi…

Arthritis Drug Seen Lowering GvHD RiskMedPage TodayATLANTA — An immunomodulatory drug approved for rheumatoid arthritis dramatically reduced the incidence of acute graft versus host disease (GvHD) in patients undergoing HLA-mismatched unrelated donor …

Arthritis Drug Seen Lowering GvHD RiskMedPage TodayATLANTA — An immunomodulatory drug approved for rheumatoid arthritis dramatically reduced the incidence of acute graft versus host disease (GvHD) in patients undergoing HLA-mismatched unrelated donor …

Economics21Copy the New Zealand Model to Compensate Organ DonorsEconomics21In 2006 the U.S. Department of Health and Human Services announced a program to help living donors reduce financial disincentives to donation, awarding a grant to help fund the …

OncLiveMost Patients in Need of HCT Can Now Get TransplantsOncLiveOverall survival and disease-free survival (DFS) are now similar in MSD and MUD recipients.3 More recently, the use of mismatched unrelated transplant, defined as high-resolution DNA mat…

OncLiveMost Patients in Need of HCT Can Now Get TransplantsOncLiveOverall survival and disease-free survival (DFS) are now similar in MSD and MUD recipients.3 More recently, the use of mismatched unrelated transplant, defined as high-resolution DNA mat…